Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
Sponsor: Pfizer
Listed as NCT00150293, this PHASE3 trial focuses on Seizure Disorder, Partial and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
AE Breda, Netherlands , Auenbruggerplatz 22, Austria , Barcelona, Spain , Barrie, Canada , Berlin, Germany , Bernau, Germany , Bialystok, Poland , Blackpool, United Kingdom , Blaricum, Netherlands , Bonn, Germany and 65 more locations